Relebactam is an inhibitor of class A b-lactamases, including KPC b-lactamases, and class C b-lactamases, and is currently under clinical development in combination with imipenem. The objective of the current study was to evaluate the in vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) submitted by clinical laboratories in 17 European countries to the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme in 2015.
Introduction
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) harbour multiple resistance elements that facilitate their 'escape' from the effects of currently marketed antimicrobial agents.
1,2 ESKAPE pathogens are increasingly responsible for antimicrobial-resistant, hospital-acquired infections worldwide and their isolation from clinical samples is associated frequently with prolonged ICU stays, residence in longterm care facilities and poor patient outcomes, particularly for patients that are immunosuppressed. [1] [2] [3] Patients infected with ESKAPE pathogens commonly receive inappropriate empirical antimicrobial therapy. 4 Delay in receiving appropriate antimicrobial therapy is the strongest predictor of mortality in critically ill patients with infections and these delays provide opportunities for spread of antimicrobial-resistant pathogens, including ESKAPE pathogens, to other patients. 2 Gram-negative ESKAPE pathogens (K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp.) are frequently MDR. [1] [2] [3] 5, 6 Clinical data suggest that infections attributable to antimicrobial-resistant pathogens, including MDR bacteria, are associated with less favourable outcomes than susceptible isolates. 7, 8 There are very few new antimicrobial agents in development to treat patients infected with these emerging MDR Gram-negative pathogens. 6, 9 b-Lactams are the largest and most frequently prescribed group of antimicrobial agents worldwide because of their proven safety V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. and efficacy. 10 They exert their antibacterial effect by inhibiting bacterial cell wall synthesis. Production of b-lactamases is one of the primary mechanisms conferring b-lactam resistance in Gram-negative bacilli. The addition of a b-lactamase inhibitor to a b-lactam is an established strategy in the development of new b-lactam antimicrobial agents. b-Lactamase inhibitors function to restore the activity of a b-lactam against previously resistant b-lactamase-producing bacteria. 11 Currently prescribed b-lactam/b-lactamase inhibitor combinations utilize the b-lactamase inhibitors clavulanate, sulbactam, tazobactam (in combination with piperacillin or ceftolozane), avibactam (in combination with ceftazidime) and vaborbactam (in combination with meropenem). Unfortunately, the older inhibitors (clavulanate, sulbactam, tazobactam) are not effective against increasingly common isolates of Gram-negative bacilli producing newer b-lactamases such as KPC b-lactamases or against isolates hyper-producing AmpC cephalosporinases. 12, 13 Carbapenems are the class of b-lactams with the broadest spectrum of antibacterial activity. They provide safe, reliable, clinically effective therapy for infections caused by aerobic and anaerobic Gram-negative and Gram-positive bacteria and are generally reserved for the treatment of patients with serious nosocomial infections and as agents of last resort. Carbapenems demonstrate stability against many b-lactamases including class A ESBLs and class C b-lactamases (AmpC b-lactamases). In Gram-negative bacteria, resistance to carbapenems may arise through production of AmpC b-lactamases, carbapenemases or ESBLs, often in combination with impaired outer membrane permeability and/or upregulated drug efflux. In addition to KPC b-lactamases, carbapenems are also hydrolysed by class B MBLs (e.g. NDM, IMP and VIM) and some class D b-lactamases such as the OXA-48-like carbapenemases in Enterobacteriaceae and OXA-23-, OXA-24/40-, OXA-51-and OXA-58-type b-lactamases found in Acinetobacter spp.
Relebactam, formerly MK-7655, is a novel, non-b-lactam bicyclic diazabicyclooctane b-lactamase inhibitor that is currently in clinical development in combination with imipenem to target infections caused by carbapenem-resistant P. aeruginosa that demonstrate resistance by porin loss combined with AmpC overexpression and imipenem-resistant Enterobacteriaceae producing any number of class A and/or C b-lactamases with or without concomitant porin loss.
14 In initial testing with limited numbers of isolates, relebactam, which is inactive when tested alone, 15 restored the in vitro activity of imipenem against many imipenem-non-susceptible Enterobacteriaceae and P. aeruginosa isolates. 14, 16 Relebactam is structurally and mechanistically related to avibactam and both inhibitors are active against class A b-lactamases, including ESBLs and KPC b-lactamases, and class C b-lactamases.
17
The intent of the current study was to determine the in vitro activities of imipenem/relebactam and comparators against Gram-negative ESKAPE pathogens isolated by hospital laboratories in 17 European countries in 2015.
Materials and methods

Bacterial isolates
Isolates tested in this study were collected as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme. SMART monitors in vitro antimicrobial susceptibility profiles of clinical isolates of aerobic and facultative Gram-negative bacilli collected by hospital laboratories worldwide from patients with intra-abdominal (since 2002), urinary tract (since 2009) and lower respiratory tract (since 2015) infections. 18 In 2015, 49 hospital laboratories in 17 European countries participated in SMART (Table 1) . Each laboratory was asked to submit consecutive clinically relevant isolates of Gram-negative bacilli from patients with intra-abdominal infections (n " 100), urinary tract infections (n " 50) and lower respiratory infections (n " 100) to International Health Management Associates, Inc. (IHMA Europe Sàrl, Monthey/VS, Switzerland), which acted as the central laboratory for this study. Only one isolate per patient per species was allowed. The 49 participating hospital laboratories collected 11064 isolates of Gram-negative bacilli from intra-abdominal infections (n " 4633), urinary tract infections (n " 2509) and lower respiratory tract infections (n " 3831); for 91 isolates the infection source was not specified. Gram 
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed at IHMA using the CLSI standard broth microdilution method 19, 20 with custom-made dehydrated Trek Diagnostic Systems panels (Thermo Scientific, Independence, OH, USA). Quality controls were performed on each day of testing using appropriate ATCC control strains, following CLSI and manufacturer guidelines. All isolates were tested against imipenem/relebactam, imipenem, amikacin, aztreonam, cefepime, ceftazidime, ceftriaxone, levofloxacin and piperacillin/tazobactam. Relebactam was tested at a fixed concentration of 4 mg/L in combination with 2-fold dilutions of imipenem, as recommended by CLSI. 20 MICs were interpreted as susceptible or resistant using EUCAST MIC clinical breakpoints. 21 Imipenem MIC breakpoints for Enterobacteriaceae and A. baumannii (susceptible, 2 mg/L; resistant, .8 mg/L) and P. aeruginosa (susceptible, 4 mg/L; resistant, .8 mg/L) were applied to MICs for imipenem in the presence of 4 mg/L relebactam for comparative purposes. 21 
Screening for b-lactamase genes
All imipenem-non-susceptible isolates of P. aeruginosa (n " 477), K. pneumoniae (n " 179) and Enterobacter spp. (n " 34) were tested for the presence of genes encoding b-lactamases using published multiplex PCR assays, followed by full-gene DNA sequencing as described previously. 22, 23 Specifically, isolates were screened for genes encoding MBLs (NDM, IMP, VIM, GIM and SPM), serine b-lactamases [KPC, GES, OXA-48-like (Enterobacteriaceae) and OXA-24-like (P. aeruginosa)], ESBLs (SHV, TEM, CTX-M, VEB, PER and GES), acquired AmpC b-lactamases (ACC, ACT, CMY, DHA, FOX, MIR and MOX) and the chromosomally encoded pseudomonal AmpC b-lactamase. Imipenem-non-susceptible isolates of A. baumannii were not characterized molecularly because the addition of relebactam to imipenem did not improve its in vitro activity against this organism.
Results
For P. aeruginosa, 72.0% of isolates were susceptible to imipenem and 94.7% of isolates were inhibited by imipenem/relebactam at the imipenem EUCAST breakpoint of 4 mg/L; the MIC 90 of imipenem (16 mg/L) was 8-fold higher than that of imipenem/relebactam (2 mg/L). Of the comparator agents, only amikacin (89.1% susceptible) demonstrated an in vitro rate of susceptibility of .80% (Table 2) . Among imipenem-non-susceptible isolates of P. aeruginosa, the in vitro activity of imipenem was restored in Imipenem/relebactam versus Gram-negative ESKAPE pathogens JAC 81.1% of isolates by the addition of relebactam. Figure 1(a) shows the effect of relebactam on the MIC distribution of imipenem against all 1705 isolates of P. aeruginosa tested and shows that the modal MIC of imipenem was lowered from 1 to 0.5 mg/L in the presence of relebactam. Figure 1(b) shows the effect of relebactam on the MIC distribution of imipenem for the 477 isolates of imipenem-non-susceptible P. aeruginosa and that the modal MIC of imipenem decreased from 8 to 2 mg/L in the presence of relebactam. Among the 81.1% (387/477) of isolates of imipenemnon-susceptible P. aeruginosa that were inhibited at imipenem/relebactam MICs of 4 mg/L, 24 isolates carried an ESBL and 4 isolates carried an acquired AmpC, while none of the acquired blactamases included in the screening algorithm were detected in the vast majority of isolates (92.8%; 359/387) (data not shown). The 90 isolates of P. aeruginosa that were non-susceptible to both imipenem and imipenem/relebactam included 53 isolates (58.9%) that carried an MBL and 19 isolates (21.1%) that carried a GES carbapenemase (Table 3 ). The 53 MBL-positive isolates comprised 46 isolates carrying VIM, 4 isolates carrying NDM and 3 isolates carrying IMP. Of the 19 isolates carrying a GES carbapenemase, 17 were collected from one hospital in Portugal. Acquired b-lactamase genes were not detected in 16.7% of isolates of P. aeruginosa that were non-susceptible to both imipenem and imipenem/ relebactam.
For K. pneumoniae, 88.7% and 94.8% of isolates were susceptible to imipenem and imipenem/relebactam, respectively, using the imipenem EUCAST breakpoint of 2 mg/L. Of the comparator agents, only amikacin showed in vitro activity (89.9% susceptible) comparable to imipenem/relebactam and imipenem; the susceptibilities to other tested agents were 60%-70%. Among imipenemnon-susceptible isolates of K. pneumoniae, the in vitro activity of imipenem was restored in 54.2% of isolates by the addition of relebactam (Table 2 ). Figure 1 shows the effect of relebactam on the MIC distribution of imipenem against all 1591 isolates of K. pneumoniae tested (Figure 1c ) and against the 179 isolates of imipenemnon-susceptible K. pneumoniae (Figure 1d) . Because of the small proportion of imipenem-non-susceptible isolates among all K. pneumoniae (11.3%), the imipenem MIC distribution was similar with and without relebactam (Figure 1c ). For the 179 isolates that were non-susceptible to imipenem, the modal MIC decreased at least 128-fold from .32 to 0.5 mg/L. Among the imipenem-nonsusceptible K. pneumoniae isolates, 44.7% (80/179) carried KPC and were inhibited by imipenem/relebactam at MICs of 2 mg/L. Among the 82 isolates that were non-susceptible to both imipenem and imipenem/relebactam, 41 (50.0%) carried an MBL with or without a serine b-lactamase ( Karlowsky et al. (Table 2 ). Of the comparator agents, only amikacin (98.2% susceptible) showed in vitro activity comparable to imipenem/relebactam and imipenem; the susceptibilities to other tested agents ranged from 88.5% (levofloxacin) to 58.6% (ceftriaxone). Figure 1 shows the effect of relebactam on the MIC distribution of imipenem against all 772 isolates of Enterobacter spp. (Figure 1e ) and against 34 isolates of imipenem-non-susceptible Enterobacter spp. (Figure 1f ). 
Discussion
Previous investigators have reported that the greatest impact of combining relebactam with imipenem was observed for isolates of carbapenem-resistant K. pneumoniae that harboured a KPC or an ESBL as well as for isolates of carbapenem-resistant P. aeruginosa with a deficit in outer membrane protein D (OprD) production combined with overexpression of the chromosomally encoded AmpC b-lactamase.
14-16,24-26 Livermore et al. 14 reported that, at a concentration of 4 mg/L, relebactam lowered imipenem MICs for Enterobacteriaceae carrying KPC from 16-64 to 0.12-1 mg/L, restoring susceptibility to imipenem for 97% of isolates. Similarly, Young et al., 25 who studied a larger collection of 145 KPC-positive K. pneumoniae (KPC-2, KPC-3, KPC-11), reported that relebactam, at a concentration of 4 mg/L, increased the percentage of isolates susceptible to imipenem from 9.9 to 98. In the current study, 54.2% (97/179) of imipenem-non-susceptible isolates of K. pneumoniae [including all (80/80) KPC-positive isolates] and 26.5% (9/34) of imipenem-non-susceptible isolates of Enterobacter spp. [including all (2/2) KPC-positive isolates] were rendered susceptible to imipenem by the addition of relebactam. Among the 82 isolates of K. pneumoniae that were not inhibited by either imipenem or imipenem/relebactam at MICs of 2 mg/L, 45 (54.9%) carried an OXA-48-type carbapenemase and 41 (50.0%) carried an MBL. Notably, both imipenem-non-susceptible, imipenem/relebactam-susceptible isolates [18.6% (18/97 isolates)] and imipenem-non-susceptible, imipenem/relebactam-non-susceptible isolates [50.0% (41/82 isolates)] were found to carry OXA-48, which may reflect different expression levels of this enzyme in these isolates or the contribution of other undetermined resistance mechanisms. The 25 isolates of Enterobacter spp. that were not inhibited by either imipenem or imipenem/relebactam MICs of 2 mg/L all carried an MBL.
Livermore et al. 14 also reported that, at a concentration of 4 mg/L, relebactam lowered imipenem MICs for imipenemresistant, MBL-negative OprD-deficient isolates of P. aeruginosa from 16-64 to 1-4 mg/L, restoring susceptibility to imipenem for nearly 60% of isolates. Lapuebla et al. 16 also reported that relebactam enhanced the activity of imipenem against P. aeruginosa, including isolates with depressed oprD and increased ampC expression. In the current study, only 5.3% of all P. aeruginosa remained non-susceptible to imipenem/relebactam and these 90 non-susceptible isolates included 53 isolates (58.9%) that carried an MBL and 19 isolates (21.1%) that carried a GES carbapenemase. To our knowledge imipenem/relebactam activity has been described against isolates carrying GES and OXA-type enzymes, but not against isolates carrying only GES carbapenemases. 24 Our data suggest that it may not be effective against this enzyme in P. aeruginosa. However, GES carbapenemases are rare 27 and our findings are based on 2 P. aeruginosa isolates carrying GES-5 from one hospital in Italy and 17 isolates carrying GES-6 from one hospital in Portugal, which may represent a clonal outbreak. Therefore, it would be prudent not to draw broad conclusions based on our data alone. Karlowsky et al.
In the current study, relebactam did not improve the activity of imipenem against clinical isolates of A. baumannii. This observation has also been made by other investigators. 16 In the current study, rates of resistance among A. baumannii to all agents tested, including amikacin, were .80%. Isolates of A. baumannii that were imipenem-non-susceptible were also almost entirely (99.8%, 436/437) non-susceptible to imipenem/relebactam. A. baumannii is intrinsically resistant to several classes of antimicrobial agents, frequently MDR, and is associated with hospitalized patients. 28 Currently, A. baumannii is an infrequent pathogen relative to the prevalence of other ESKAPE pathogens; however, variability in its geographic prevalence has been observed. 28 Limitations of the current study include small numbers of participating hospital laboratories in many countries and the corresponding small sample sizes, which did not allow an in-depth analysis of country-specific b-lactamase prevalence or susceptibility patterns. Imipenem/relebactam versus Gram-negative ESKAPE pathogens JAC Therefore, the country-specific data we have described must be viewed with some caution. Furthermore, the wider application of the regional results is limited by national sampling variations, with more sites participating or submitting isolates in some countries compared with others, as well as the possible clonal dissemination of resistance mechanisms in some countries. As MIC interpretative breakpoints for imipenem/relebactam have not yet been published, our choice to interpret imipenem/relebactam MICs using imipenem MIC breakpoints may over-or under-call susceptibility to imipenem/ relebactam. Imipenem/relebactam has successfully completed two Phase 2 clinical trials for treating complicated intra-abdominal infections and complicated urinary tract infections and currently is in Phase 3 development with two additional clinical trials, the first for the treatment of hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia (500/250 mg administered intravenously every 6 h) and the second for the treatment of complicated intra-abdominal infections and complicated urinary tract infections (200/100 to 500/250 mg, depending on renal function, by intravenous infusion every 6 h). 29 We conclude that relebactam frequently restores the in vitro activity of imipenem against carbapenem-non-susceptible isolates of the ESKAPE pathogens P. aeruginosa, K. pneumoniae and Enterobacter spp. Treatment with polymyxins, tigecycline and aminoglycosides has been associated with significant morbidities, including nephrotoxicity, ototoxicity and cholestatic jaundice. Further development of imipenem/relebactam appears worthwhile as it may provide a valuable therapeutic option for treating patients with infections caused by carbapenem-non-susceptible isolates of Gram-negative bacilli, including ESKAPE pathogens. Karlowsky et al.
